Zydus Pharmaceuticals recalled Chlorpromazine Hydrochloride Tablets on September 3, 2025. The recall affects a specific lot due to contamination with N-Nitroso Desmethyl Chlorpromazine. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: N/A
Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 100-count bottle. Manufactured by Zydus Lifesciences Ltd., Baddi, India, and distributed by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ. NDC: 70710-1129-1.
The recall results from CGMP deviations, specifically the presence of N-Nitroso Desmethyl Chlorpromazine above the acceptable intake limit. This contamination poses serious health risks.
No specific incidents or injuries have been reported in relation to this recall. The contamination risk is significant enough to warrant immediate action.
Consumers should stop using Chlorpromazine Hydrochloride Tablets immediately. Contact Zydus Pharmaceuticals or a healthcare provider for further guidance.
For assistance, call Zydus Pharmaceuticals (USA) Inc. at 1-800-XXX-XXXX. Visit the FDA recall page for more information.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.